Future Oncology’s 2025 roundup presents a curated selection of lung cancer articles highlighting key research and potential clinical impact.
A White Paper in the collection examines the value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in metastatic non-small-cell lung cancer (mNSCLC). Treatment of metastatic NSCLC has become increasingly personalized with therapies directed at specific oncogenic drivers. For rare drivers with small patient populations, randomized controlled trials face obstacles including enrollment challenges, limited patient representation and prolonged timelines. The White Paper outlines how real-world evidence—drawn from registries, electronic health records and observational cohorts—can complement randomized trials, strengthen evidence generation and better inform treatment decisions.
The roundup highlights these discussions alongside other articles that may influence clinical practice and research priorities in lung cancer care.
Leave a Reply